Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (vol 120, pg 612, 2019)

被引：4

作者：

Serrano, Cesar ^{[1
,2
,3
,4
]}

Marino-Enriquez, Adrian ^{[1
]}

Tao, Derrick L. ^{[1
]}

Ketzer, Julia ^{[5
]}

Eilers, Grant ^{[1
]}

Zhu, Meijun ^{[1
]}

Yu, Channing ^{[2
,6
,15
]}

Mannan, Aristotle M. ^{[6
]}

Rubin, Brian P. ^{[7
,8
]}

Demetri, George D. ^{[2
,9
,10
]}

Raut, Chandrajit P. ^{[2
,11
]}

Presnell, Ajia ^{[12
,13
]}

McKinley, Arin ^{[12
,13
]}

Heinrich, Michael C. ^{[12
,13
]}

Czaplinski, Jeffrey T. ^{[2
]}

Sicinska, Ewa ^{[14
]}

Bauer, Sebastian ^{[5
]}

George, Suzanne ^{[2
]}

Fletcher, Jonathan A. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, 20 Shattuck St,Thorn 528, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Vall dHebron Inst Oncol, Sarcoma Translat Res Lab, Barcelona, Spain

[4] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany

[6] Broad Inst MIT & Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA

[7] Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave, Cleveland, OH USA

[8] Cleveland Clin, 9500 Euclid Ave, Cleveland, OH 44106 USA

[9] Dana Farber Canc Inst, Ludwig Ctr Canc Res, Boston, MA USA

[10] Harvard Med Sch, Boston, MA 02115 USA

[11] Harvard Med Sch, Brigham & Womens Hosp, Div Surg Oncol, 75 Francis St, Boston, MA 02115 USA

[12] Portland VA Med Ctr, Portland, OR USA

[13] OHSU Knight Canc Inst, Portland, OR USA

[14] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA

[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 121卷 / 03期

关键词：

D O I：

10.1038/s41416-019-0487-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:

引用

页码：281 / 281

页数：1

共 20 条

[1] Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano
Adrián Mariño-Enríquez
Derrick L. Tao
Julia Ketzer
Grant Eilers
Meijun Zhu
Channing Yu
Aristotle M. Mannan
Brian P. Rubin
George D. Demetri
Chandrajit P. Raut
Ajia Presnell
Arin McKinley
Michael C. Heinrich
Jeffrey T. Czaplinski
Ewa Sicinska
Sebastian Bauer
Suzanne George
Jonathan A. Fletcher
British Journal of Cancer, 2019, 120 : 612 - 620
[2] Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Serrano, Cesar
Marino-Enriquez, Adrian
Tao, Derrick L.
Ketzer, Julia
Eilers, Grant
Zhu, Meijun
Yu, Channing
Mannan, Aristotle M.
Rubin, Brian P.
Demetri, George D.
Raut, Chandrajit P.
Presnell, Ajia
McKinley, Arin
Heinrich, Michael C.
Czaplinski, Jeffrey T.
Sicinska, Ewa
Bauer, Sebastian
George, Suzanne
Fletcher, Jonathan A.
BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 612 - 620
[3] Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano
Adrián Mariño-Enríquez
Derrick L. Tao
Julia Ketzer
Grant Eilers
Meijun Zhu
Channing Yu
Aristotle M. Mannan
Brian P. Rubin
George D. Demetri
Chandrajit P. Raut
Ajia Presnell
Arin McKinley
Michael C. Heinrich
Jeffrey T. Czaplinski
Ewa Sicinska
Sebastian Bauer
Suzanne George
Jonathan A. Fletcher
British Journal of Cancer, 2019, 121 : 281 - 281
[4] Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
Nishida, Toshirou
Kanda, Tatsuo
Nishitani, Akiko
Takahashi, Tsuyoshi
Nakajima, Kiyokazu
Ishikawa, Takashi
Hirota, Seiichi
CANCER SCIENCE, 2008, 99 (04): : 799 - 804
[5] Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
Ken-Hong Lim
Ming-Jer Huang
Li-Tzong Chen
Tsang-En Wang
Chien-Liang Liu
Cheng-Shyong Chang
Mei-Chin Liu
Reuy-Kuen Hsieh
Chin-Yuan Tzen
Medical Oncology, 2008, 25 : 207 - 213
[6] Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
Lim, Ken-Hong
Huang, Ming-Jer
Chen, Li-Tzong
Wang, Tsang-En
Liu, Chien-Liang
Chang, Cheng-Shyong
Liu, Mei-Chin
Hsieh, Reuy-Kuen
Tzen, Chin-Yuan
MEDICAL ONCOLOGY, 2008, 25 (02) : 207 - 213
[7] Novel tyrosine kinase inhibitors with antiproliferative activity against imatinib-resistant cell lines
Lerma, E
Nguyen, V
Wang, T
Tipping, A
Melo, J
Austin, D
Deisseroth, A
EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 227 - 228
[8] Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor
Wada, Noriko
Kurokawa, Yukinori
Takahashi, Tsuyoshi
Hamakawa, Takuya
Hirota, Seiichi
Naka, Tetsuji
Miyazaki, Yasuhiro
Makino, Tomoki
Yamasaki, Makoto
Nakajima, Kiyokazu
Takiguchi, Shuji
Mori, Masaki
Doki, Yuichiro
ONCOLOGY, 2016, 90 (02) : 112 - 117
[9] Detecting secondary C-KIT mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor
Wada, N.
Kurokawa, Y.
Takahashi, T.
Hamakawa, T.
Hirota, S.
Serada, S.
Naka, T.
Miyazaki, Y.
Makino, T.
Yamasaki, M.
Nakajima, K.
Takiguchi, S.
Mori, M.
Doki, Y.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S62 - S62
[10] Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors
Noriko Wada
Tsuyoshi Takahashi
Yukinori Kurokawa
Kiyokazu Nakajima
Toshirou Nishida
Masahiro Koh
Yusuke Akamaru
Masaaki Motoori
Yutaka Kimura
Koji Tanaka
Yasuhiro Miyazaki
Tomoki Makino
Makoto Yamasaki
Hidetoshi Eguchi
Yuichiro Doki
Surgery Today, 2021, 51 : 1506 - 1512

← 1 2 →